Laurus LabsQ1 FY25

Laurus Labs Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹2,338P/E: 94.3Market Cap: ₹1.3L CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3
  • Q1 FY25 revenue was flattish at Rs. 1,195 crores, expected to pick up in H2 FY25 due to clinical phase project deliveries.
  • Oncology APIs growing strongly, with Q1 sales up 120% YoY; new oncology products validated, awaiting regulatory approvals.
  • ARV franchise expected to remain stable at around Rs. 2,400-2,500 crores annually.
  • CDMO business anticipates healthy growth supported by late-stage NCE project deliveries scheduled in Q4 FY25.
  • Commercial supplies from about 10 products ongoing; new registrations and late-stage projects indicate commercial volumes likely from FY26.
  • Expansion plans (formulations, fermentation facility at Vizag, animal health, crop protection) targeting medium to long-term growth.
  • Pipeline includes 62 products under review/development with significant addressable market value.
  • CMO collaborations and expanded oral solid dosage manufacturing lines expected to contribute to future revenue growth.

See what Laurus Labs management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • The transcript does not mention any specific plans for new fundraising through debt or equity in the near term.
  • Current net debt stands at Rs. 2,633 crores, with a target to reduce the net debt to EBITDA ratio to less than 2.5 by March 2025.
  • CAPEX of around Rs. 1800 to Rs. 2000 crores is planned over the next two years, primarily funded by advances from customers for specific CMO capacity expansions and internal resources.
  • The company is prioritizing investments into high-value business segments and improving working capital efficiency without indicating the need for immediate external funding.
  • No explicit mention of fresh equity issuance or debt raising during this period was found in the transcript.

See what Laurus Labs management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Capex planned for FY24 and FY25 is around Rs. 1800 to Rs. 2000 crores, mainly directed toward CDMO and finished dosage formulations (FDF) expansion.
  • Additional FDF capacity expansion at Unit-2 in Vizag: increasing from 10 billion to 13 billion tablets over 18 months, driven by specific customer CMO contracts, mostly for generic products; majority of this CAPEX will be funded by customer advances.
  • Rs. 200 crore investment planned into fermentation facility at Vizag, expected to be commissioned by mid-2026, focusing on GMP pharmaceutical manufacturing.
  • Ongoing investment in new R&D center at Genome Valley to support expanded CDMO capabilities.
  • Total historic CAPEX of Rs. 2600 crore of which around 75% is for CDMO projects, currently underutilized due to phased project execution.
  • Long-term investments include Animal Health and Crop Protection Ingredients facilities, with Crop Protection qualification targeted by end FY25.

Track Laurus Labs — get its next earnings analysis in your feed

How does Laurus Labs rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisLaurus Labs
Rev 3Mar 3

How does Laurus Labs rank in Pharmaceuticals & Biotechnology?

Compare Laurus Labs against every Pharmaceuticals & Biotechnology company (Q1 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →